Seattle Genetics to Host Conference Call and Webcast Discussion of Fourth Quarter and Year 2015 Financial Results on February 9, 2016

BOTHELL, Wash.--(BUSINESS WIRE)--

Seattle Genetics, Inc. SGEN announced today that it will report its fourth quarter and year 2015 financial results on Tuesday, February 9 after the close of financial markets. Following the results announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows:

LIVE access on Tuesday, February 9, 2016

1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time

• Telephone 888-510-1765 (domestic) or 719-325-2402 (international); conference ID 8644672
• Webcast available at www.seattlegenetics.com in the Investors and News section

REPLAY access

• Telephone replay will be available beginning at approximately 4:30 p.m. PT on Tuesday, February 9, 2016 through 5:00 p.m. PT on Thursday, February 11, 2016 by calling 888-203-1112 (domestic) or 719-457-0820 (international); conference ID 8644672
• Webcast replay will be available on the Seattle Genetics website at www.seattlegenetics.com in the Investors and News section

About Seattle Genetics

Seattle Genetics is a biotechnology company focused on the development and commercialization of innovative antibody-based therapies for the treatment of cancer. Seattle Genetics is leading the field in developing antibody-drug conjugates (ADCs), a technology designed to harness the targeting ability of antibodies to deliver cell-killing agents directly to cancer cells. The company's lead product, ADCETRIS^® (brentuximab vedotin), is a CD30-targeted ADC that, in collaboration with Takeda Pharmaceutical Company Limited, is commercially available in more than 55 countries, including the U.S., Canada, Japan and members of the European Union. Additionally, ADCETRIS is being evaluated broadly in more than 70 ongoing clinical trials in CD30-expressing malignancies. Seattle Genetics is also advancing vadastuximab talirine (SGN-CD33A; 33A), an ADC that is expected to advance into a phase 3 trial for acute myeloid leukemia in 2016. Beyond ADCETRIS and 33A, the company is developing a robust pipeline of clinical-stage programs, including denintuzumab mafodotin (SGN-CD19A; 19A), SGN-LIV1A, ASG-15ME, ASG-22ME, SGN-CD70A and SEA-CD40. Seattle Genetics has collaborations for its ADC technology with a number of leading biotechnology and pharmaceutical companies, including AbbVie, Agensys (an affiliate of Astellas), Bayer, Genentech, GlaxoSmithKline and Pfizer. More information can be found at www.seattlegenetics.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160120005338/en/